Edition:
India

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,554JPY
28 Jun 2017
Change (% chg)

¥5 (+0.32%)
Prev Close
¥1,549
Open
¥1,534
Day's High
¥1,561
Day's Low
¥1,532
Volume
2,199,700
Avg. Vol
1,184,432
52-wk High
¥2,134
52-wk Low
¥1,532

4506.T

Chart for 4506.T

About

Sumitomo Dainippon Pharma Co., Ltd., formerly Dainippon Sumitomo Pharma Co.,Ltd., is a pharmaceutical company. The Japan division manufactures and sells ethical and general use drugs. The North America division manufactures, develops, purchases and sells ethical drugs through its consolidated subsidiaries. The China division... (more)

Overall

Beta: 0.72
Market Cap(Mil.): ¥616,347.31
Shares Outstanding(Mil.): 397.90
Dividend: 9.00
Yield (%): 1.16

Financials

  4506.T Industry Sector
P/E (TTM): 21.23 13.64 17.41
EPS (TTM): 72.97 -- --
ROI: 5.30 -6.98 -5.24
ROE: 6.39 -6.46 -4.49

BRIEF- Sumitomo Chemical unit Sumitomo Dainippon Pharma announces unblinding of phase 3 study of Napabucasin

* Says its unit Sumitomo Dainippon Pharma Co Ltd announced today that the company decided to unblind the BRIGHTER study, a phase 3 global study in patients with gastric and gastro-esophageal junction (GEJ) cancer of napabucasin, an investigational cancer stemness inhibitor, based on a recommendation by the study’s independent Data and Safety Monitoring Board (DSMB), following a pre- specified interim analysis

26 Jun 2017

BRIEF- Sumitomo Dainippon Pharma announces application of International Financial Reporting Standards

* Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan-Generally Accepted Accounting Principles

29 May 2017

BRIEF-Sumitomo Dainippon Pharma unit receives Complete Response Letter from FDA for SUN-101/eFlow® New Drug Application for chronic obstructive pulmonary disease

* Says its US-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for SUN-101/eFlow®(glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),including chronic bronchitis and/or emphysema, on May 26 (US Eastern time)

29 May 2017

BRIEF-Sumitomo Dainippon Pharma looks to expand applications of drug candidate Dasotraline - Nikkei

* Sumitomo Dainippon Pharma Co Ltd looks to expand the applications of its drug candidate dasotraline - Nikkei

25 Mar 2017

More From Around the Web

Earnings vs. Estimates